Allergy Therapeutics Share Discussion Threads

[totally banjo] 14/10/2024 14:17

Preliminary results are due in the next few weeks which will be interesting to see if sales of existing products have increased during that time frame and after.

There's obviously a lot going on in the background regarding trials and licenses so we might get an update on progress.

[joeblogg2] 14/10/2024 13:29

Thanks banjo just hope it is not a discounted issue

[totally banjo] 14/10/2024 10:54

Hi Joe, all I know is what has been via RNS with an update 1st October 2024:

Update on funding and preliminary results


01 October 2024 Allergy Therapeutics plc (AIM: AGY), the integrated commercial biotechnology company specialising in allergy vaccines, today announces an update on the Group's working capital position.

Following tight cost control initiatives and changes to the phasing of R&D expenditure, the Group has successfully extended its cash runway into late-October.

There remains a further £12.5m of uncommitted funding available under the Amended Loan Facility and the Company is at an advanced stage on further debt funding to support its ongoing operations and development pipeline.

Preparation of Allergy Therapeutics' preliminary financial results for the year ended 30 June 2024 is well underway and the Group now expects to publish its report by the end of October.

[joeblogg2] 14/10/2024 08:53

Guys before I buy more what type of funding ?

[totally banjo] 09/10/2024 13:18

Hi Joe, I'm not sure how much the peanut (PROTECT) trial costs but it won't be cheap! Therefore you would think AGY must believe they have a 90%+ chance of a successful outcome?

[joeblogg2] 09/10/2024 11:54

guys have been following agy for years and have bought a few on spread with IG as my cash situation pretty bad these days due to losses over the years. Funding is needed for ongoing trials , the peanut one they must have some idea if it works or not by now as safety seems ok??

[totally banjo] 08/10/2024 23:37

Jimmy, I don't think funding is a problem at all! It shows confidence in the ongoing trials success and the huge rewards that will come from it but obviously investors want results before investing,imo.

What I find intriguing is that when I first bought in many years ago they used to have regular video interviews with Manuel Llobet but they appear to have stopped! Although not that important were of interest in keeping investors informed in a visual way.

Possibly the reason is due to the backing they have now and there is end game in view if all goes to plan, I don't know!

[jimmyloser] 08/10/2024 10:50

Thanks coin. Good to know.

[coinbase] 08/10/2024 10:26

Winterflood have dropped the ask, narrowing the spread to 6.78%.

[totally banjo] 07/10/2024 23:52

Hi Jimmy, one thing I've noticed, the market from when I started nearly 30 years ago and after having a near 10 year lapse due to getting badly burnt has changed quite dramatically! There appears to be less interest or maybe a sea change (whatever that means) in the way shares are bought and sold especially in AIM and the 'longer view' or maybe it's just me!

AGY have stated they expect the results for the year ended 30 June 2024 to be published by end of this month which they didn't have to say but it's good to hear anyway, as it gives everyone a rough time for information, which is great!

Over the next few weeks (Results) and months there is so much positive news that could easily get the share price into double figures as in 10p or even a lot further!

If the Results can show an increase in revenue on their existing products after investment in improving their manufacturing facilities to cope with the demand for their products than that's a massive bonus!

The ongoing trials along with getting approvals for their various new products is and should be classed as 'potential' regarding any share price movement as anything could happen!

I bought some more last week as I believe the company has a very exciting future ahead but that's just my opinion!

[jimmyloser] 07/10/2024 14:59

Here is a little reminder of some snippets from recent RNS’s - DYOR

22/7/2024
• Significant cost reductions made - overheads expected to be significantly lower than prior year
• The shareholders are aware of the Group funding needs over the next 12 months and remain supportive of the business
• The Group intends to submit an MAA to PEI in Q4 2024 and this remains on track.
• The completion of the G309 and G306 field studies represents a significant milestone in plans for registration in the US. Following an earlier successful end of phase II meeting with the FDA, the subsequent studies were designed to support a pathway forward to BLA in the US with both G309 and G306 studies including US subjects and it is also planned to include US subjects in the upcoming five-year long paediatric study (G308), which is expected to begin later in 2024.
• The PROTECT trial continues to run as planned and data observed thus far supports the hypo-allergic safety profile of VLP Peanut which is a key step in realising its potential as a transformative option for peanut allergy sufferers. Efficacy suggestive biomarker analysis is expected to be available in Q4 2024.

27/08/2024
• The Company continues to explore further funding options to support its ongoing operations and development pipeline.

17/09/2024
• As announced in June 2024, healthy subjects in the PROTECT trial have now received a 400-fold dose increase of VLP Peanut, providing strong confidence that the VLP technology within the vaccine candidate is safe and well tolerated at high cumulative doses.
• The preliminary results from the first two cohorts of peanut allergic patients assessing safety and efficacy are expected in Q4 2024.
• The data gathered through the PROTECT trial continues to be encouraging, as is the safety review committee's decision to proceed with higher doses in subsequent cohorts. We are keen to present preliminary efficacy data based upon biomarkers by the end of this year."

1/10/2024
• The Company is at an advanced stage on further debt funding to support its ongoing operations and development pipeline.
• Preparation of Allergy Therapeutics' preliminary financial results for the year ended 30 June 2024 is well underway and the Group now expects to publish its report by the end of October.

[totally banjo] 03/10/2024 12:12

Ah ha, that's how you post pictures nowadays!

Hi coin, there's little interest in AGY at moment so if I remember right the MM's won't want to hold many so hence the big spread, hopefully this will change in the next few weeks!

[jimmyloser] 03/10/2024 11:24

They will have a reason I expect. I am really optimistic and I expect the 'unexpected' when it comes to fund raising. impo, we are in very safe hands with the guys at Cavendish.

[coinbase] 02/10/2024 08:23

L2: 7 (1,050,000 @ 4) v 7 (1,050,000 @ 5).

[totally banjo] 01/10/2024 18:46

That was a good informative update this morning, all going to plan!

[jimmyloser] 01/10/2024 13:05

Encapsulated in a sentence - impo

"The Group now expects to publish its report by the end of October".

[jimmyloser] 01/10/2024 06:30

That RNS makes me smile,"Show me the holes"

Think about it.

[totally banjo] 25/9/2024 23:07

Jimmy, they are obviously keen (as you are well aware) especially if results go to plan in proclaiming this news to the global market as it 'could' be the making of the company! Very exciting times if and that's still a big if all goes to plan!

[jimmyloser] 25/9/2024 20:09

Just why would they be "KEEN"

A few words that carry so much weight...impo

From the last RNS 17/09/2024
We are....... keen....... to present preliminary efficacy data based upon biomarkers by the end of this year."

[coinbase] 23/9/2024 11:31

Jimmy, like you I am waiting with bated breath.

[totally banjo] 20/9/2024 19:55

There's obviously something happening looking at the chart!

[totally banjo] 19/9/2024 21:45

Hi Jimmy, do you mean the new funding agreement initially announced on 27th December 2023?

I'm no expert but with the various trials ongoing and future approvals to be obtained depending on the trial outcomes doesn't come cheep! There has also been the costs regarding building up the manufacturing facilities to meet the demand for their current products!

The longer term funding is in place up to January 2026 with Warrants issued to the lenders at a price of 4p which are exercisable until January 2027.

Therefore I assume the share price will stay around the 4p mark until we start getting real positive news from the company, just my take on the situation.